What's Happening
Moderna and Merck announced positive Phase 3 trial results for their combination melanoma vaccine pairing mRNA therapy with Keytruda, sending Moderna stock up sharply in premarket trading. The trial represents what the companies are calling a "landmark moment" in treatment for one of the deadliest forms of cancer.
Market Impact
Moderna's stock doubled on the news, making it one of the largest premarket movers. The result validates the mRNA platform beyond infectious disease and opens a significant new revenue stream for both Moderna and Merck, with potential blockbuster economics if the therapy gains regulatory approval.
Broader Implications
This success strengthens the case for mRNA technology as a durable platform across oncology, potentially reshaping the competitive landscape in cancer therapeutics and justifying the sector's premium valuations.